Satoshi Okumura

Satoshi Okumura

Auto-generated profile, based on publicly available information

Satoshi Okumura

Affiliation Department of Physiology, Tsurumi University School of Dental Medicine, Yokohama, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SOSatoshi Okumura
Satoshi Okumura
TFTakayuki Fujita
Takayuki Fujita
WCWenqian Cai
Wenqian Cai
MJMeihua Jin
Meihua Jin
INIyuki Namekata
Iyuki Namekata
YIYoshihiro Ishikawa
Yoshihiro Ishikawa
PKA phosphorylates multiple molecules involved in calcium (Ca2+) handling in cardiac myocytes and is considered to be the predominant regulator of β-adrenergic receptor–mediated enhancement of cardiac contractility; however, recent identification of exchange protein activated by cAMP (EPAC), which is independently activated by cAMP, has challenged this paradigm. Mice lacking Epac1 (Epac1 KO) exhibited decreased cardiac contractility with reduced phospholamban (PLN) phosphorylation at serine-16, the major PKA-mediated phosphorylation site. In Epac1 KO mice, intracellular Ca2+ storage and the magnitude of Ca2+ movement were decreased; however, PKA expression remained unchanged, and activation of PKA with isoproterenol improved cardiac contractility. In contrast, direct activation of EPAC in cardiomyocytes led to increased PLN phosphorylation at serine-16, which was dependent on PLC and PKCε. Importantly, Epac1 deletion protected the heart from various stresses, while Epac2 deletion was not protective. Compared with WT mice, aortic banding induced a similar degree of cardiac hypertrophy in Epac1 KO; however, lack of Epac1 prevented subsequent cardiac dysfunction as a result of decreased cardiac myocyte apoptosis and fibrosis. Similarly, Epac1 KO animals showed resistance to isoproterenol- and aging-induced cardiomyopathy and attenuation of arrhythmogenic activity. These data support Epac1 as an important regulator of PKA-independent PLN phosphorylation and indicate that Epac1 regulates cardiac responsiveness to various stresses.

1 August 2017 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
Masanari UmemuraMasanari Umemura
Masanari Umemura
Jeong-Hwan KimJeong-Hwan Kim
Jeong-Hwan Kim
HAHaruki Aoyama
Haruki Aoyama
YHYujiro Hoshino
Yujiro Hoshino
HFHidenobu Fukumura
Hidenobu Fukumura
YIYoshihiro Ishikawa
Yoshihiro Ishikawa
Iron-salen, i.e., μ-oxo-N,N'-bis(salicylidene)ethylenediamine iron (Fe(Salen)) was a recently identified as a new anti-cancer compound with intrinsic magnetic properties. Chelation therapy has been widely used in management of metallic poisoning, because an administration of agents that bind metals can prevent potential lethal effects of particular metal. In this study, we confirmed the therapeutic effect of deferoxamine mesylate (DFO) chelation against Fe(Salen) as part of the chelator antidote efficacy. DFO administration resulted in reduced cytotoxicity and ROS generation by Fe(Salen) in cancer cells. DFO (25 mg/kg) reduced the onset of Fe(Salen) (25 mg/kg)-induced acute liver and renal dysfunction. DFO (300 mg/kg) improves survival rate after systematic injection of a fatal dose of Fe(Salen) (200 mg/kg) in mice. DFO enables the use of higher Fe(Salen) doses to treat progressive states of cancer, and it also appears to decrease the acute side effects of Fe(Salen). This makes DFO a potential antidote candidate for Fe(Salen)-based cancer treatments, and this novel strategy could be widely used in minimally-invasive clinical settings.

8 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DUDaisuke Umeki
Daisuke Umeki
YOYoshiki Ohnuki
Yoshiki Ohnuki
YMYasumasa Mototani
Yasumasa Mototani
KSKouichi Shiozawa
Kouichi Shiozawa
KSKenji Suita
Kenji Suita
SOSatoshi Okumura
Satoshi Okumura
Glucocorticoid has a direct catabolic effect on skeletal muscle, leading to muscle atrophy, but no effective pharmacotherapy is available. We reported that clenbuterol (CB) induced masseter muscle hypertrophy and slow-to-fast myosin heavy chain (MHC) isoform transition through direct muscle β2-adrenergic receptor stimulation. Thus, we hypothesized that CB would antagonize glucocorticoid (dexamethasone; DEX)-induced muscle atrophy and fast-to-slow MHC isoform transition. We examined the effect of CB on DEX-induced masseter muscle atrophy by measuring masseter muscle weight, fiber diameter, cross-sectional area, and myosin heavy chain (MHC) composition. To elucidate the mechanisms involved, we used immunoblotting to study the effects of CB on muscle hypertrophic signaling (insulin growth factor 1 (IGF1) expression, Akt/mammalian target of rapamycin (mTOR) pathway, and calcineurin pathway) and atrophic signaling (Akt/Forkhead box-O (FOXO) pathway and myostatin expression) in masseter muscle of rats treated with DEX and/or CB. Masseter muscle weight in the DEX-treated group was significantly lower than that in the Control group, as expected, but co-treatment with CB suppressed the DEX-induced masseter muscle atrophy, concomitantly with inhibition of fast-to-slow MHC isoforms transition. Activation of the Akt/mTOR pathway in masseter muscle of the DEX-treated group was significantly inhibited compared to that of the Control group, and CB suppressed this inhibition. DEX also suppressed expression of IGF1 (positive regulator of muscle growth), and CB attenuated this inhibition. Myostatin protein expression was unchanged. CB had no effect on activation of the Akt/FOXO pathway. These results indicate that CB antagonizes DEX-induced muscle atrophy and fast-to-slow MHC isoform transition via modulation of Akt/mTOR activity and IGF1 expression. CB might be a useful pharmacological agent for treatment of glucocorticoid-induced muscle atrophy.

1 July 2017 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
HJHuiling Jin
Huiling Jin
TFTakayuki Fujita
Takayuki Fujita
MJMeihua Jin
Meihua Jin
RKReiko Kurotani
Reiko Kurotani
INIyuki Namekata
Iyuki Namekata
YIYoshihiro Ishikawa
Yoshihiro Ishikawa

1 July 1999 in Molecular Endocrinology
Verified
Journal Article
Closed access
CSCarsten Schwencke
Carsten Schwencke
MYManabu Yamamoto
Manabu Yamamoto
SOSatoshi Okumura
Satoshi Okumura
YTYoshiyuki Toya
Yoshiyuki Toya
SKSong-Jung Kim
Song-Jung Kim
YIYoshihiro Ishikawa
Yoshihiro Ishikawa
The cAMP-signaling pathway is composed of multiple components ranging from receptors, G proteins, and adenylyl cyclase to protein kinase A. A common view of the molecular interaction between them is that these molecules are disseminated on the plasma lipid membrane and random collide with each other to transmit signals. A limitation to this idea, however, is that a signaling cascade involving multiple components may not occur rapidly. Caveolae and their principal component, caveolin, have been implicated in transmembrane signaling, particularly in G protein-coupled signaling. We examined whether caveolin interacts with adenylyl cyclase, the membrane-bound enzyme that catalyzes the conversion of ATP to cAMP. When overexpressed in insect cells, types III, IV, and V adenylyl cyclase were localized in caveolin-enriched membrane fractions. Caveolin was coimmunoprecipitated with adenylyl cyclase in tissue homogenates and copurified with a polyhistidine-tagged form of adenylyl cyclase by Ninitrilotriacetic acid resin chromatography in insect cells, suggesting the colocalization of adenylyl cyclase and caveolin in the same microdomain. Further, the regulatory subunit of protein kinase A (RIIalpha, but not RIalpha) was also enriched in the same fraction as caveolin. Gsalpha was found in both caveolin-enriched and non-caveolin-enriched membrane fractions. Our data suggest that the cAMP-signaling cascade occurs within a restricted microdomain of the plasma membrane in a highly organized manner.

25 November 2014 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
YOYoshiki Ohnuki
Yoshiki Ohnuki
DUDaisuke Umeki
Daisuke Umeki
YMYasumasa Mototani
Yasumasa Mototani
HJHuiling Jin
Huiling Jin
WCWenqian Cai
Wenqian Cai
SOSatoshi Okumura
Satoshi Okumura